Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 1/2015

01-12-2015 | Review

Long-term sequelae from acute kidney injury: potential mechanisms for the observed poor renal outcomes

Authors: Matt Varrier, Lui G Forni, Marlies Ostermann

Published in: Critical Care | Issue 1/2015

Login to get access

Abstract

This article is one of ten reviews selected from the Annual Update in Intensive Care and Emergency Medicine 2015 and co-published as a series in Critical Care. Other articles in the series can be found online at http://​ccforum.​com/​series/​annualupdate2015​. Further information about the Annual Update in Intensive Care and Emergency Medicine is available from http://​www.​springer.​com/​series/​8901.
Literature
1.
Hsu RK, McCulloch CE, Dudley RA, Lo LJ, Hsu CY. Temporal changes in incidence of dialysis-requiring AKI. J Am Soc Nephrol. 2013;24:37–42.PubMed
2.
Hsu CY, Vittinghoff E, Lin F, Shlipak MG. The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. Ann Intern Med. 2004;141:95–101.PubMed
3.
Okusa MD, Chertow GM, Portilla D. The nexus of acute kidney injury, chronic kidney disease, and World Kidney Day 2009. Clin J Am Soc Nephrol. 2009;4:520–2.PubMedPubMedCentral
4.
Chawla LS, Eggers PW, Star RA, Kimmel PL. Acute kidney injury and chronic kidney disease as interconnected syndromes. N Engl J Med. 2014;371:58–66.PubMed
5.
Leung KC, Tonelli M, James MT. Chronic kidney disease following acute kidney injury-risk and outcomes. Nat Rev Nephrol. 2012;9:77–85.PubMed
6.
Venkatachalam MA, Griffin KA, Lan R, Geng H, Saikumar P, Bidani AK. Acute kidney injury: a springboard for progression in chronic kidney disease. Am J Physiol Renal Physiol. 2010;298:F1078–94.PubMedPubMedCentral
7.
Lo LJ, Go AS, Chertow GM, et al. Dialysis-requiring acute renal failure increases the risk of progressive chronic kidney disease. Kidney Int. 2009;76:893–9.PubMedPubMedCentral
8.
Bucaloiu ID, Kirchner HL, Norfolk ER, Hartle JE, Perkins RM. Increased risk of death and de novo chronic kidney disease following reversible acute kidney injury. Kidney Int. 2012;81:477–85.PubMed
9.
Prowle JR, Kolic I, Purdell-Lewis J, Taylor R, Pearse RM, Kirwan DJ. Serum creatinine changes associated with critical illness and detection of persistent renal dysfunction after AKI. Clin J Am Soc Nephrol. 2014;9:1015–23.PubMedPubMedCentral
10.
Wald R, Quinn RR, Luo J, et al. University of Toronto Acute Kidney Injury Research Group: Chronic dialysis and death among survivors of acute kidney injury requiring dialysis. JAMA. 2009;302:1179–85.PubMed
11.
Ishani A, Xue JL, Himmelfarb J, et al. Acute kidney injury increases risk of ESRD among elderly. J Am Soc Nephrol. 2009;20:223–8.PubMedPubMedCentral
12.
Chawla LS, Amdur RL, Amodeo S, Kimmel PL, Palant CE. The severity of acute kidney injury predicts progression to chronic kidney disease. Kidney Int. 2011;79:1361–9.PubMedPubMedCentral
13.
Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int. 2012;81:442–8.PubMed
14.
Go AS, Parikh CR, Ikizler TA. The assessment, serial evaluation, and subsequent sequelae of acute kidney injury (ASSESS-AKI) study: design and methods. BMC Nephrol. 2010;11:22.PubMedPubMedCentral
15.
Grams ME, Astor BC, Bash LD, Matsushita K, Wang Y, Coresh J. Albuminuria and estimated glomerular filtration rate independently associate with acute kidney injury. J Am Soc Nephrol. 2012;21:1757–64.
16.
James MT, Hemmelgarn BR, Wiebe N, et al. Alberta Kidney Disease Network: Glomerular filtration rate, proteinuria, and the incidence and consequences of acute kidney injury: a cohort study. Lancet. 2010;376:2096–103.PubMed
17.
Harel Z, Bell CM, Dixon SN, et al. Predictors of progression to chronic dialysis in survivors of severe acute kidney injury: a competing risk study. BMC Nephrol. 2014;15:114.PubMedPubMedCentral
18.
Hsu C, Ordonez J, Chertow G, Fan D, McCulloch C, Go A. The risk of acute renal failure in patients with chronic kidney disease. Kidney Int. 2008;74:101–7.PubMedPubMedCentral
19.
Zhan M, Brooks C, Liu F, Sun L, Dong Z. Mitochondrial dynamics: regulatory mechanisms and emerging role in renal pathophysiology. Kidney Int. 2013;83:568–81.PubMedPubMedCentral
20.
Brooks C, Wei Q, Cho SG, Dong Z. Regulation of mitochondrial dynamics in acute kidney injury in cell culture and rodent models. J Clin Invest. 2009;119:1275–85.PubMedPubMedCentral
21.
Funk JA, Schnellmann RG. Persistent disruption of mitochondrial homeostasis after acute kidney injury. Am J Physiol Renal Physiol. 2012;302:F853–64.PubMed
22.
Horbelt M, Lee SY, Mang HE. Acute and chronic microvascular alterations in a mouse model of ischemic acute kidney injury. Am J Physiol Renal Physiol. 2007;293:F688–95.PubMed
23.
Basile DP, Friedrich JL, Spahic J. Impaired endothelial proliferation and mesenchymal transition contribute to vascular rarefaction following acute kidney injury. Am J Physiol Renal Physiol. 2011;300:F721–33.PubMed
24.
Yuan HT, Li XZ, Pitera JE, Long DA, Woolf AS. Peritubular capillary loss after mouse acute nephrotoxicity correlates with down-regulation of vascular endothelial growth factor-A and hypoxia-inducible factor-1 alpha. Am J Pathol. 2003;163:2289–301.PubMedPubMedCentral
25.
Loeffler I, Wolf G. Transforming growth factor-beta and the progression of renal disease. Nephrol Dial Transplant. 2014;29 Suppl 1:i37–45.PubMed
26.
27.
Kinsey GR, Li L, Okusa MD. Inflammation in acute kidney injury. Nephron Exp Nephrol. 2008;109:e102–7.PubMed
28.
Gentle ME, Shi S, Daehn I. Epithelial cell TGFbeta signaling induces acute tubular injury and interstitial inflammation. J Am Soc Nephrol. 2013;24:787–99.PubMedPubMedCentral
29.
Gewin L, Vadivelu S, Neelisetty S. Deleting the TGF-beta receptor attenuates acute proximal tubule injury. J Am Soc Nephrol. 2012;23:2001–11.PubMedPubMedCentral
30.
Basile DP, Donohoe D, Roethe K, Osborn JL. Renal ischemic injury results in permanent damage to peritubular capillaries and influences long-term function. Am J Physiol Renal Physiol. 2001;281:F887–99.PubMed
31.
Tsakas S, Goumenos DS. Accurate measurement and clinical significance of urinary transforming growth factor-beta1. Am J Nephrol. 2006;26:186–93.PubMed
32.
Dhaun N, Webb DJ. The road from AKI to CKD: the role of endothelin. Kidney Int. 2013;84:637–8.PubMed
33.
Mino N, Kobayashi M, Nakajima A, et al. Protective effect of a selective endothelin receptor antagonist, BQ-123, in ischemic acute renal failure in rats. Eur J Pharmacol. 1992;221:77–83.PubMed
34.
Lopez-Farre A, Gomez-Garre D, Bernabeu F, Lopez-Novoa JM. A role for endothelin in the maintenance of post-ischaemic renal failure in the rat. J Physiol. 1991;444:513–22.PubMedPubMedCentral
35.
Clozel M, Ramuz H, Clozel JP, et al. Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use. J Pharmol Exp Ther. 1999;290:840–6.
36.
Abu-Saleh N, Ovcharenko E, Awad H, et al. Involvement of the endothelin and nitric oxide systems in the pathogenesis of renal ischemic damage in an experimental diabetic model. Life Sci. 2012;91:669–75.PubMed
37.
Forbes JM, Hewitson TD, Becker GJ, Jones CL. Simultaneous blockade of endothelin A and B receptors in ischemic acute renal failure is detrimental to long-term kidney function. Kidney Int. 2001;59:1333–41.PubMed
38.
Forbes JM, Leaker B, Hewitson TD, Becker GJ, Jones CL. Macrophage and myofibroblast involvement in ischemic acute renal failure is attenuated by endothelin receptor antagonists. Kidney Int. 1999;55:198–208.PubMed
39.
Fenhammar J, Andersson A, Forestier J, et al. Endothelian receptor A antagonism attenuates renal medullary blood flow impairment in endotoxemic pigs. PLoS One. 2011;6:e21534.PubMedPubMedCentral
40.
Gellai M, Jugus M, Fletcher T, DeWolf R, Nambi P. Reversal of postischemic acute renal failure with a selective endothelin A receptor antagonist in the rat. J Clin Invest. 1994;93:900–6.PubMedPubMedCentral
41.
Zager RA, Johnson ACM, Andress D, Becker K. Progressive endothelin-1 gene activation initiates chronic/end-stage renal disease following experimental ischemic/reperfusion injury. Kidney Int. 2013;84:703–12.PubMedPubMedCentral
42.
Arfian N, Emoto N, Vignon-Zellweger N, Nakayama K, Yagi K, Hirata K. ET-1 deletion from endothelial cells protects the kidney during the extension phase of ischemia/reperfusion injury. Biochem Biophys Res Commun. 2012;425:443–9.PubMed
43.
Gulmen S, Kiris I, Narin C, et al. Tezosentan reduces the renal injury induced by abdominal aortic ischemia-reperfusion in rats. J Surg Res. 2009;157:e7–e13.PubMed
44.
Cummings RD, Liu F-T, et al. Galectins. In: Varki A, Cummings RD, Esko JD, editors. Essentials of Glycobiology. 2nd ed. New York: Cold Spring Harbor Laboratory Press; 2009. p. 475–88.
45.
Calvier L, Miana M, Reboul P, et al. Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol. 2013;33:67–75.PubMed
46.
Lalancette-Hebert M, Swarup V, Beaulieu JM, et al. Galectin-3 is required for resident microglia activation and proliferation in response to ischemic injury. J Neurosci. 2012;32:10383–95.PubMedPubMedCentral
47.
Henderson NC, Mackinnon AC, Farnworth SL, et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci USA. 2006;103:5060–5.PubMedPubMedCentral
48.
Nishi Y, Sano H, Kawashima T, et al. Role of galectin-3 in human pulmonary fibrosis. Allergol Int. 2007;56:57–65.PubMed
49.
Lippert E, Falk W, Bataille F, et al. Soluble galectin-3 is a strong, colonic epithelial-cell-derived, lamina propria fibroblast-stimulating factor. Gut. 2007;56:43–51.PubMed
50.
Henderson NC, Mackinnon AC, Farnworth SL, et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol. 2008;172:288–98.PubMedPubMedCentral
51.
Mackinnon AC, Gibbons MA, Farnworth SL, et al. Regulation of transforming growth factor-beta1-driven lung fibrosis by galectin-3. Am J Respir Crit Care Med. 2012;185:537–46.PubMedPubMedCentral
52.
Sasaki S, Bao Q, Hughes RC. Galectin-3 modulates rat mesangial cell proliferation and matrix synthesis during experimental glomerulonephritis induced by anti-Thy1.1 antibodies. J Pathol. 1999;187:481–9.PubMed
53.
O’Seaghdha CM, Hwang SJ, Ho JE, Vasan RS, Levy D, Fox CS. Elevated galectin-3 precedes the development of CKD. J Am Soc Nephrol. 2013;24:1470–7.PubMedPubMedCentral
54.
Chen K, Jiang RJ, Wang CQ, et al. Predictive value of plasma galectin-3 in patients with chronic heart failure. Eur Rev Med Pharmacol Sci. 2013;17:1005–11.PubMed
55.
Fermann GJ, Lindsell CJ, Storrow AB, et al. Galectin 3 complements BNP in risk stratification in acute heart failure. Biomarkers. 2012;17:706–13.PubMedPubMedCentral
56.
Gopal DM, Kommineni M, Ayalon N, et al. Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure. J Am Heart Assoc. 2012;1:e000760.PubMedPubMedCentral
57.
Ho JE, Liu C, Lyass A, et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol. 2012;60:1249–56.PubMedPubMedCentral
58.
Lok DJ, Klip IT, Lok SI, et al. Incremental prognostic power of novel biomarkers (growth-differentiation factor-15, high-sensitivity C-reactive protein, galectin-3, and high-sensitivity troponin-T) in patients with advanced chronic heart failure. Am J Cardiol. 2013;112:831–7.PubMed
59.
Tsai TH, Sung PH, Chang LT, et al. Value and level of galectin-3 in acute myocardial infarction patients undergoing primary percutaneous coronary intervention. J Atheroscler Thromb. 2012;19:1073–82.PubMed
60.
van der Velde AR, Gullestad L, Ueland T, et al. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circ Heart Fail. 2013;6:219–26.PubMed
61.
Weir RA, Petrie CJ, Murphy CA, et al. Galectin-3 and cardiac function in survivors of acute myocardial infarction. Circ Heart Fail. 2013;6:492–8.PubMed
62.
de Boer RA, Yu L, van Veldhuisen DJ. Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep. 2010;7:1–8.PubMedPubMedCentral
63.
Tang WH, Shrestha K, Shao Z, et al. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol. 2011;108:385–90.PubMedPubMedCentral
64.
Lok DJ, Van Der Meer P, de la Porte PW, et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol. 2010;99:323–8.PubMedPubMedCentral
65.
Shah RV, Chen-Tournoux AA, Picard MH, Kimmenade RR, Januzzi JL. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail. 2010;12:311–9.
66.
Nishiyama J, Kobayashi S, Ishida A, et al. Up-regulation of galectin-3 in acute renal failure of the rat. Am J Pathol. 2000;157:815–23.PubMedPubMedCentral
67.
Fernandes Bertocchi AP, Campanhole G, Wang PH, et al. A Role for galectin-3 in renal tissue damage triggered by ischemia and reperfusion injury. Transpl Int. 2008;21:999–1007.PubMed
68.
Kolatsi-Joannou M, Price KL, Winyard PJ, Long DA. Modified citrus pectin reduces galectin-3 expression and disease severity in experimental acute kidney injury. PLoS One. 2011;6:e18683.PubMedPubMedCentral
69.
Heyman SN, Evans RG, Rosen S, Rosenberger C. Cellular adaptive changes in AKI: mitigating renal hypoxic injury. Nephrol Dial Transplant. 2012;27:1721–8.PubMed
70.
Epstein FH. Oxygen and renal metabolism. Kidney Int. 1997;51:381–5.PubMed
71.
Gunaratnam L, Bonventre JV. HIF in kidney disease and development. J Am Soc Nephrol. 2009;20:1877–87.PubMed
72.
Nangaku M, Rosenberger C, Heyman SN, Eckardt KU. Regulation of hypoxia-inducible factor in kidney disease. Clin Exp Pharmacol Physiol. 2013;40:148–57.PubMed
73.
Schietke RE, Hackenbeck T, Tran M, et al. Renal tubular HIF-2α expression requires VHL inactivation and causes fibrosis and cysts. PLoS One. 2012;7:e31034.PubMedPubMedCentral
Metadata
Title
Long-term sequelae from acute kidney injury: potential mechanisms for the observed poor renal outcomes
Authors
Matt Varrier
Lui G Forni
Marlies Ostermann
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Critical Care / Issue 1/2015
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/s13054-015-0805-0

Other articles of this Issue 1/2015

Critical Care 1/2015 Go to the issue

Letter

Is epinephrine during cardiac arrest associated with worse outcomes in resuscitated patients? Effect of vasopressin and catecholamines on the migration of leukocytes

Letter

Value of the cuff leak test is limited

Viewpoint

Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants

Research

Automated drug dispensing systems in the intensive care unit: a financial analysis

Research

Effects of different types of fluid resuscitation for hemorrhagic shock on splanchnic organ microcirculation and renal reactive oxygen species formation

Research

The potential utility of urinary biomarkers for risk prediction in combat casualties: a prospective observational cohort study